KURMA, Keerthi; BOIZARD MORACCHINI, Andrea; GALLI, Gael; JEAN, Mickael; VACHER, Pierre; BLANCO, Patrick; LEGEMBRE, Patrick

doi:10.1016/j.bbcan.2021.188596

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

KURMA, Keerthi

BOIZARD MORACCHINI, Andrea

Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

GALLI, Gael

Langue

Article de revue

Ce document a été publié dans

Biochimica et Biophysica Acta - Reviews on Cancer. 2021, vol. 1876, n° 2

Résumé en anglais

Although CD95L (also known as FasL) is still predominantly considered as a death ligand that induces apoptosis in infected and transformed cells, substantial evidence indicate that it can also trigger non-apoptotic signaling pathways whose pathophysiological roles remain to be fully elucidated. The transmembrane ligand CD95L belongs to the tumor necrosis factor (TNF) superfamily. After cleavage by metalloprotease, its soluble form (s-CD95L) fails to trigger the apoptotic program but instead induces signaling pathways promoting the aggressiveness of certain inflammatory disorders such as autoimmune diseases and cancers. We propose to evaluate the various pathologies in which the metalloprotease-cleaved CD95L is accumulated and analyze whether this soluble ligand may play a significant role in the pathology progression. Based on the TNF?-targeting therapeutics, we envision that targeting the soluble form of CD95L may represent a very attractive therapeutic option in the pathologies depicted herein.< Réduire

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche